WO2007016532A3 - Mutations and polymorphisms of hdac4 - Google Patents

Mutations and polymorphisms of hdac4 Download PDF

Info

Publication number
WO2007016532A3
WO2007016532A3 PCT/US2006/029851 US2006029851W WO2007016532A3 WO 2007016532 A3 WO2007016532 A3 WO 2007016532A3 US 2006029851 W US2006029851 W US 2006029851W WO 2007016532 A3 WO2007016532 A3 WO 2007016532A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac4
mutations
mutant
polymorphisms
various aspects
Prior art date
Application number
PCT/US2006/029851
Other languages
French (fr)
Other versions
WO2007016532A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007016532A2 publication Critical patent/WO2007016532A2/en
Publication of WO2007016532A3 publication Critical patent/WO2007016532A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC4 gene. The invention provides new HDAC4 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC4 mutations of the invention, expression vectors encoding the HDAC4 mutant polypeptides of the invention and organisms that express the HDAC4 mutant and polymorphic polynucleotides and/or HDAC4 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC4 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/029851 2005-08-02 2006-07-31 Mutations and polymorphisms of hdac4 WO2007016532A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70492405P 2005-08-02 2005-08-02
US60/704,924 2005-08-02

Publications (2)

Publication Number Publication Date
WO2007016532A2 WO2007016532A2 (en) 2007-02-08
WO2007016532A3 true WO2007016532A3 (en) 2008-01-10

Family

ID=37709300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029851 WO2007016532A2 (en) 2005-08-02 2006-07-31 Mutations and polymorphisms of hdac4

Country Status (1)

Country Link
WO (1) WO2007016532A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL205531B1 (en) 2002-03-13 2010-04-30 Janssen Pharmaceutica Nv Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003076438A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
ATE396971T1 (en) 2002-03-13 2008-06-15 Janssen Pharmaceutica Nv SULFONYLAMINO DERIVATIVES AS NEW INHIBITORS OF HISTONE DEACETYLASE
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
EP1942882A2 (en) * 2005-10-24 2008-07-16 Novartis AG Combination of histone deacetylase inhibitors and radiation
JP5137848B2 (en) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1981875T3 (en) 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv SUBSTITUTED INDOLYLALKYLAMINODE DERIVATIVES AS INHIBITORS OF HISTONDEACETYLASE
SI1981874T1 (en) 2006-01-19 2009-10-31 Janssen Pharmaceutica Nv Aminophenyl derivatives as novel inhibitors of histone deacetylase
BRPI0716838A2 (en) * 2006-09-15 2013-10-01 Janssen Pharmaceutica Nv combinations of class I specific histone deacetylase inhibitors with proteosome inhibitors
US8912153B2 (en) * 2008-08-13 2014-12-16 President And Fellows Of Harvard College HDAC4 nucleic acid administration to treat retinal disease
CN110404072B (en) * 2018-04-26 2021-08-06 天津医科大学 Application of substance for inhibiting phosphorylation of 357 th tyrosine residue of YAP protein in preventing atherosclerosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAI ANTONELLO ET AL: "HISTONE DEACETYLATION IN EPIGENETICS: AN ATTRACTIVE TARGET FOR ANTICANCER THERAPY", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 25, no. 3, May 2005 (2005-05-01), pages 261 - 309, XP009075075, ISSN: 0198-6325 *
PARK JUNG MIN ET AL: "No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer.", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION : A PUBLICATION OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, COSPONSORED BY THE AMERICAN SOCIETY OF PREVENTIVE ONCOLOGY JUL 2005, vol. 14, no. 7, July 2005 (2005-07-01), pages 1841 - 1843, XP002424811, ISSN: 1055-9965 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US9150560B2 (en) 2002-03-13 2015-10-06 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US9533979B2 (en) 2002-03-13 2017-01-03 Janssen Pharmaceutica Nv Amino-derivatives as novel inhibitors of histone deacetylase
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8592441B2 (en) 2004-07-28 2013-11-26 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase

Also Published As

Publication number Publication date
WO2007016532A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2005114190A3 (en) Methods of identifying biomarkers
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
EP2011885A3 (en) Method of diagnosing bladder cancer
WO2006135879A3 (en) Diagnosis and prognosis of diabetes
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
NZ600235A (en) Methods and compositions for the assessment of drug response
WO2009077864A3 (en) Compositions and methods of detecting tiabs
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
WO2006073682A3 (en) Diagnostic test
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
ATE432997T1 (en) THERAPY MONITORING FOR TUMORS USING ACC133 MRNA
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
BR0111473A (en) Methods for screening an individual for glycogen storage disease, for screening an individual for pomp disease, for monitoring the clinical condition of an individual with pomp disease, to estimate the efficacy of a therapeutic regimen for an individual with disease pompe and to determine the concentration of an oligosaccharide in a biological sample
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
AU2006228990A8 (en) A method of diagnosis and treatment and agents useful for same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06789060

Country of ref document: EP

Kind code of ref document: A2